PT  - JOURNAL ARTICLE
AU  - Henry P. Oswin
AU  - Allen E. Haddrell
AU  - Mara Otero-Fernandez
AU  - Jamie F.S. Mann
AU  - Tristan A. Cogan
AU  - Tom Hilditch
AU  - Jianghan Tian
AU  - Dan Hardy
AU  - Darryl J. Hill
AU  - Adam Finn
AU  - Andrew D. Davidson
AU  - Jonathan P. Reid
TI  - The Dynamics of SARS-CoV-2 Infectivity with Changes in Aerosol Microenvironment
AID  - 10.1101/2022.01.08.22268944
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.08.22268944
4099  - http://medrxiv.org/content/early/2022/01/10/2022.01.08.22268944.short
4100  - http://medrxiv.org/content/early/2022/01/10/2022.01.08.22268944.full
AB  - Understanding the factors that influence the airborne survival of viruses such as SARS-CoV-2 in aerosols is important for identifying routes of transmission and the value of various mitigation strategies for preventing transmission. We present measurements of the stability of SARS-CoV-2 in aerosol droplets (∼5-10µm equilibrated radius) over timescales spanning from 5 seconds to 20 minutes using a novel instrument to probe survival in a small population of droplets (typically 5-10) containing ∼1 virus/droplet. Measurements of airborne infectivity change are coupled with a detailed physicochemical analysis of the airborne droplets containing the virus. A decrease in infectivity to ∼10 % of the starting value was observable for SARS-CoV-2 over 20 minutes, with a large proportion of the loss occurring within the first 5 minutes after aerosolisation. The initial rate of infectivity loss was found to correlate with physical transformation of the equilibrating droplet; salts within the droplets crystallise at RHs below 50% leading to a near instant loss of infectivity in 50–60% of the virus. However, at 90% RH the droplet remains homogenous and aqueous, and the viral stability is sustained for the first 2 minutes, beyond which it decays to only 10% remaining infectious after 10 minutes. The loss of infectivity at high RH is consistent with an elevation in the pH of the droplets, caused by volatilisation of CO2 from bicarbonate buffer within the droplet. Three different variants of SARS-CoV-2 were compared and found to have a similar degree of airborne stability at both high and low RH.Significance The aerosol microenvironment is highly dynamic exposing pathogens, such as the SARS-CoV-2 virus when exhaled in respiratory aerosol, to extreme conditions of solute concentration, pH and evaporative cooling. Yet surviving this environment is a key step in the transmission of such pathogens. Understanding the impact that airborne transport has on pathogens and the influence of environmental conditions on pathogen survival can inform the implementation of strategies to mitigate the spread of diseases such as COVID-19. We report changes in the infectivity of the airborne virus over timescales spanning from 5 s to 20 minutes and demonstrate the role of two microphysical processes in this infectivity loss: particle crystallisation and aerosol droplet pH change.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the NIHR-UKRI rapid COVID-19 call, the Elizabeth Blackwell Institute for Health Research, the University of Bristol, and the Medical Research Council. Additionally, this work was supported by funding from the PROTECT COVID-19 National Core Study on transmission and environment, managed by the Health and Safety Executive on behalf of HM Government. AH and MOF received funding from the BBSRC, project BB/T011688/1. HO is supported by funding from DSTL and EPSRC. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors